Can Gut Hormones Control Appetite and Prevent Obesity?
- Owais B. Chaudhri, PHD,
- Katie Wynne, PHD and
- Stephen R. Bloom, MD, DSC
- From the Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital, London, U.K
- Address correspondence and reprint requests to Professor S.R. Bloom, Department of Metabolic Medicine, Imperial College London, 6th Floor Commonwealth Building, Hammersmith Hospital, Du Cane Rd., London W12 0NN, U.K. E-mail: s.bloom{at}imperial.ac.uk
Abstract
The current obesity epidemic is fuelled by the availability of highly palatable, calorie-dense food, and the low requirement for physical activity in our modern environment. If energy intake exceeds energy use, the excess calories are stored as body fat. Although the body has mechanisms that act to maintain body weight over time, they primarily defend against starvation and are less robust in preventing the development of obesity. Knowledge of this homeostatic system that controls body weight has increased exponentially over the last decade and has revealed new possibilities for the treatment of obesity and its associated comorbidities. One therapeutic target is the development of agents based on the gastrointestinal hormones that control appetite. This review discusses the hormones oxyntomodulin, peptide YY, glucagon-like peptide 1, pancreatic polypeptide, and ghrelin and their emerging potential as anti-obesity treatments.
- CNS, central nervous system
- DPP-IV, dipetidyl peptidase IV
- GI, gastrointestinal
- GLP, glucagon-like peptide
- OXM, oxyntomodulin
- PYY, peptide YY
Footnotes
-
S.R.B. is on the board of and holds stock in Thiakis. O.B.C. and K.W. declare no relevant conflict of interest.
-
This article is based on a presentation at the 1st World Congress of Controversies in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this article were made possible by unrestricted educational grants from MSD, Roche, sanofi-aventis, Novo Nordisk, Medtronic, LifeScan, World Wide, Eli Lilly, Keryx, Abbott, Novartis, Pfizer, Generx Biotechnology, Schering, and Johnson & Johnson.
- DIABETES CARE














